How Much Vitamin K2 Should You Take a Day?

Most clinical trials on vitamin K2 supplements use daily doses between 90 and 200 micrograms of the MK-7 form, with 180 µg being the most frequently studied amount for bone and cardiovascular outcomes. No government has set a separate recommended daily intake for K2 specifically, which leaves the dosing question to be answered by the research literature rather than official guidelines. The picture gets more complicated once you realize that K2 comes in several forms, each absorbed differently, and that one common medication can turn even a small K2 dose into a serious concern.

Why the Form of K2 Changes the Dose

Vitamin K2 is not a single molecule. It is a family of compounds called menaquinones, numbered by the length of their chemical side chain. The two forms you will encounter in supplements are MK-4 and MK-7. They behave quite differently in your body, and the dose that works for one does not apply to the other.

MK-4 has poor bioavailability at nutritional doses. In a head-to-head comparison with MK-7, researchers found that MK-4 had a short half-life in the blood and was barely detectable after oral supplementation at normal dietary levels, while MK-7 was well absorbed and remained measurable in the bloodstream for much longer.¹ Vitamin K1 and MK-4 clear from plasma within about 8 to 24 hours, whereas long-chain menaquinones like MK-7 can still be detected up to 96 hours after a single dose.² This longer half-life is the main reason MK-7 has become the preferred supplement form: a once-daily dose builds stable blood levels that cover you around the clock.

Because of this difference, Japanese clinical research on MK-4 for osteoporosis has typically used pharmacological doses of 45 milligrams per day, hundreds of times higher than MK-7 supplement doses. That dose is treated as a prescription drug in Japan, not a dietary supplement. When people ask “how much K2 should I take,” they almost always mean MK-7, and the evidence-based range for MK-7 is far lower.

What the Bone Health Trials Actually Used

The strongest evidence for MK-7 supplementation and bone health comes from trials in postmenopausal women, a group at elevated risk of bone loss. A three-year Dutch trial gave 244 healthy postmenopausal women either 180 µg of MK-7 daily or a placebo. The MK-7 group had significantly less decline in bone mineral content and bone mineral density at the lumbar spine and femoral neck, and bone strength measures also improved.³

A Chinese trial took a slightly different approach, testing lower doses. In that study, 311 men and postmenopausal women aged 50 to 75 were split into groups receiving either a placebo, 50 µg/day, 90 µg/day, or 90 µg/day combined with calcium and vitamin D. After one year, the 90 µg groups showed significantly less bone loss at the femoral neck in postmenopausal women compared to placebo. Interestingly, adding calcium and vitamin D did not provide an additional benefit beyond the 90 µg of K2 alone in that trial.⁴ The 50 µg dose did not produce statistically significant results, suggesting that somewhere around 90 µg is a practical minimum for bone benefits.

The mechanism behind these effects involves a protein called osteocalcin. Vitamin K2 helps activate osteocalcin through a process called carboxylation, which allows the protein to bind calcium and direct it into bone tissue. K2 also promotes osteoblast activity and several growth factors involved in bone formation.⁵ Without adequate K2, a portion of your osteocalcin circulates in its inactive, undercarboxylated form, and researchers use this ratio as a marker for K2 status.

Doses Studied for Arteries and the Heart

Vitamin K2 also activates another protein called Matrix Gla Protein, or MGP, which is the body’s most potent natural inhibitor of soft-tissue calcification. When MGP is not properly carboxylated due to insufficient vitamin K, calcium can accumulate in arterial walls and heart valves instead of staying in bones.⁶ This is sometimes described as the “calcium paradox” of aging: bones lose calcium while arteries gain it, and vitamin K2 deficiency may contribute to both problems simultaneously.

The main cardiovascular trial for MK-7 used the same 180 µg daily dose as the bone trial. In that double-blind study of healthy postmenopausal women, three years of MK-7 supplementation significantly improved arterial stiffness compared to placebo.⁷ Arterial stiffness is a meaningful predictor of cardiovascular events, so this is a clinically relevant finding, though it does not directly measure whether supplementation prevents heart attacks or strokes.

In patients with chronic kidney disease, who are at especially high risk of vascular calcification, a small study tested 90 µg of MK-7 daily combined with vitamin D for about nine months. The group receiving K2 showed significantly less thickening of the carotid artery wall compared to vitamin D alone, along with a decrease in markers of inactive MGP.⁸ The study was small, so the findings are suggestive rather than definitive, but they point to K2 playing a protective role in vascular health at doses well within the 90–200 µg range.

Pairing K2 with Vitamin D

Vitamins D and K2 work on overlapping calcium pathways. Vitamin D increases calcium absorption from the gut and promotes the production of vitamin K-dependent proteins like osteocalcin and MGP. But those proteins need vitamin K2 to become activated through carboxylation.⁹ Taking vitamin D without adequate K2 means your body produces more of these proteins but cannot fully activate them.

Clinical evidence supports the combination. In one trial of postmenopausal women with osteoporosis, those receiving both vitamin D3 and vitamin K2 for two years saw a bone mineral density increase of roughly 5%, while those receiving K2 alone saw almost no change.¹⁰ A separate trial found that the combination of D3 and K2 increased lumbar spine BMD significantly more than either vitamin alone or calcium.¹¹ If you are already supplementing with vitamin D, adding K2 is the logical next step to ensure the calcium your body absorbs ends up in the right places.

Safety at Typical and High Doses

Vitamin K2 has a remarkably clean safety profile. No tolerable upper intake level has been set by major regulatory bodies because toxicity has been so hard to produce. In animal testing, the no-observed-adverse-effect level for MK-7 administered daily for 90 days was 10 mg per kilogram of body weight, the highest dose the researchers tested, and they still found no toxic effects.¹² A more recent and extensive toxicological evaluation set the no-adverse-effect level at 4,500 mg per kilogram per day in rats, with no significant changes across dozens of examined parameters including organ weight, blood chemistry, and histopathology.¹³ To put that in perspective, a 70 kg person scaled equivalently would be taking hundreds of thousands of micrograms, far beyond any supplement dose.

In human studies, MK-7 has shown no adverse effects at the doses typically tested. A review of the pediatric and maternal literature concluded that the lack of adverse effects makes MK-7 a suitable choice for supplementation in pregnant and nursing women and in children with various health conditions.¹⁴ None of this means that megadosing is a good idea, but the evidence suggests that doses in the 90–200 µg range carry essentially no risk for people not taking blood thinners.

The Warfarin Exception

There is one group for whom even small amounts of vitamin K2 are a serious concern: people taking warfarin or other vitamin K antagonist anticoagulants. Warfarin works by blocking the same enzyme that vitamin K uses to activate clotting factors. K2 and warfarin compete directly for this enzyme, so supplementing with K2 can blunt warfarin’s anticoagulant effect.¹⁵

The sensitivity is surprisingly high. In a dose-response study with healthy volunteers, a daily intake of just 45 µg of MK-7 significantly lowered INR (the standard measure of warfarin’s effectiveness) and altered clotting markers. Even doses as low as 10 or 20 µg were judged to cause clinically relevant INR drops in a substantial proportion of subjects.¹⁶ This means that K2 supplement doses considered beneficial for bones and arteries are the same doses that can destabilize anticoagulation. If you take warfarin, do not add a K2 supplement without close monitoring by your prescriber. Newer anticoagulants like rivaroxaban work through a different mechanism and do not interact with vitamin K in the same way.

Food Sources and Practical Intake

Among dietary sources of MK-7, natto, the Japanese fermented soybean product, is in a class by itself. A single 50-gram serving provides roughly 380 µg of MK-7, more than double the highest dose used in most clinical trials.¹⁷ Research from Japan indicates that daily intake of around 100–200 µg of MK-7 maintains stable circulating levels and supports bone health, with approximately 100 µg daily bringing blood levels to about 1.5 nanomoles per liter, the upper end of the normal range.

Other fermented foods contain K2, but in much smaller amounts. Hard and aged cheeses like Gouda and Emmental provide moderate levels of longer-chain menaquinones. Egg yolks and dark-meat poultry contain MK-4 but, as discussed earlier, MK-4 is poorly absorbed at dietary doses. For most people outside of Japan, where natto is a daily staple for many, getting consistent K2 intake through food alone is difficult. This is why supplementation fills a practical gap.

When choosing a supplement, fat-soluble vitamins are better absorbed with a meal containing some fat. In people with fat malabsorption conditions like cystic fibrosis, liposomal delivery forms have shown improved vitamin status. A trial in cystic fibrosis patients found that a liposomal formulation enriched with K2 reduced the percentage of undercarboxylated osteocalcin more effectively than standard supplementation.¹⁸ For people with normal digestion, a standard MK-7 capsule taken with food works fine.

Children, Pregnancy, and Preterm Infants

Vitamin K2 deficiency during pregnancy is more common than you might expect. A study of nearly 200 mother-newborn pairs found that about 39% of mothers had vitamin K2 deficiency in late pregnancy, and those mothers had significantly lower K2 blood levels than the control group.¹⁹ Since K2 plays a role in bone metabolism through osteocalcin activation, low maternal levels could affect fetal skeletal development, though the clinical significance of this is still being studied.

In preterm infants, a randomized trial found that adding vitamins A and K2 to routine vitamin D and K1 supplementation for 12 months led to higher lumbar spine and femur bone mineral density, better growth, and improved micronutrient status, with no increase in adverse reactions.²⁰ Pediatric doses are not standardized, and the evidence is still early, but the safety profile of MK-7 is reassuring enough that researchers are comfortable studying it in vulnerable populations.

How to Know If Your Intake Is Enough

There is no routine blood test for vitamin K2 itself in standard medical practice, but researchers use two functional biomarkers. Circulating undercarboxylated osteocalcin reflects K2 status in bone, while desphospho-uncarboxylated Matrix Gla Protein (dp-ucMGP) reflects K2 status in the vascular system.²¹ High levels of either marker suggest that your body has more of these proteins than it can activate with the vitamin K available, which points toward insufficiency. In clinical trials, supplementation with MK-7 consistently brings these markers down, confirming that the doses tested are functionally effective.

These tests are not widely available through standard healthcare channels and are mostly used in research settings. For practical purposes, most healthy adults who eat very little natto and no K2 supplement are probably getting less than optimal amounts. The typical Western diet provides plenty of vitamin K1 from green vegetables, which is sufficient for blood clotting, but K1 and K2 are distributed differently in the body. K1 is preferentially taken up by the liver for clotting factor production, while K2 reaches bones and arterial walls more effectively.²² Eating your spinach keeps your blood clotting normally but does not necessarily supply your skeleton or arteries with the K2 they need.

Emerging Research in Dental and Oral Health

One area of K2 research that rarely makes it into supplement marketing is dental health. Vitamin K2 activates osteocalcin and other proteins involved in the mineralization of hard tissues, and teeth are hard tissue. Early laboratory work has explored whether K2 can support dental procedures. In one recent study, vitamin K2 applied to dentin samples enhanced the migration and attachment of dental stem cells and increased the expression of proteins involved in dentin and cementum formation, including osteocalcin and dentin sialophosphoprotein.²³ This is test-tube research, not clinical evidence, and nobody should expect a K2 pill to regrow a tooth. But it does illustrate that the proteins K2 activates are involved in calcified tissues beyond bone, which may eventually broaden the clinical applications of supplementation in directions we have not yet mapped.